[Eliana/CAR T-cell therapy]
Therapy persistence is a vital factor in determining the success of CAR-Ts for blood cancers like leukemia. While CAR-Ts hold great promise for blood cancers such as leukemia, in some cases, the durability of the treatment falls short, leading to a potential relapse. A positive study from researchers at University College London, Great Ormond Street Hospital and the Wellcome Sanger Institute, published in Nature Medicine sheds light on the challenge and ways to address it. Examining CAR T-cell therapy persistence in the CARPALL trialInvestigating patients from the phase 1 CARPALL trial, the study considered patients who underwent CAR T-cell therapy (AUTO1) to treat B-cell acute lymphoblastic leukemia (B-ALL), a rare and aggressive pediatric blood cancer. Focusing on an advanced therapy investigational medicinal product (ATIMP) designed to combat CD19+ or CD22+ acute lymphoblastic le…